Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 20,999 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune System Disorders Clear all
Terminated Phase 1 Interventional

Iododoxorubicin in Treating Patients With Primary Systemic Amyloidosis

NCT00030381
View directory record Official record
Conditions
Primary Systemic Amyloidosis
Interventions
4'-iodo-4'-deoxydoxorubicin, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

Chewed vs. Crushed Lanthanum Carbonate in Hemodialysis Patients

NCT00660530
View directory record Official record
Conditions
Hyperphosphatemia, Kidney Disease
Interventions
Lanthanum Carbonate Chewable Product, Lanthanum carbonate crushed powder
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 24, 2026, 10:57 AM EDT
Completed No phase listed Observational Results available

Validation of the Hospital Asthma Severity Score (HASS)

NCT02782065
View directory record Official record
Conditions
Asthma
Interventions
Not an interventional study
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

NCT00288028
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 24, 2026, 10:57 AM EDT
Not listed Phase 2 Interventional Results available

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

NCT00791700
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
2 Years to 18 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 24, 2026, 10:57 AM EDT
Completed No phase listed Observational

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

NCT06526000
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 24, 2026, 10:57 AM EDT
Not listed Phase 2 Interventional

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

NCT00017992
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 10:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Comparison of Microglial Activation in Severe Asthma and Healthy Controls

NCT06299592
View directory record Official record
Conditions
Asthma
Interventions
PET/MRI using [18F]FEPPA tracer
Combination Product
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

NCT01997411
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Nasal Glucagon, Intramuscular Glucagon
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
4 Years to 16 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 24, 2026, 10:57 AM EDT
Terminated Phase 2 Interventional Results available

Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia

NCT03094611
View directory record Official record
Conditions
CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

NCT02793544
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL), Chemotherapy-sensitive Lymphoma, Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma, Acute Myelogenous Leukemia (AML), Acute Biphenotypic Leukemia (ABL), Acute Undifferentiated Leukemia (AUL)
Interventions
Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1, Infusion of non-T-cell depleted bone marrow on Day 0, Busulfan, Cyclophosphamide 50mg/kg/day IV on Days -2,-1, Cyclophosphamide 50mg/kg/day IV on Days -5,-4, Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1, Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4, Sirolimus, Mycophenolate mofetil, G-CSF, Pre-HCT Mesna on Days -6 and -5, Pre-HCT Mesna on Days -2 and -1, Pre-HCT Mesna on Days -5 and -4, Post-HCT Mesna
Drug · Radiation · Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
15 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
11
States / cities
Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examining the Role of Genetics in Determining the Immune Response to an HIV Vaccine in HIV-Uninfected Adult Twins

NCT01054872
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 DNA plasmid vaccine, HIV-1 recombinant Ad5 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug Users

NCT00841477
View directory record Official record
Conditions
Hepatitis B Infection, Hepatitis C Infection, HIV Infection
Interventions
hepatitis B vaccine 3 dose schedule (0,1,2 month), HBV Vaccination Self-Efficacy Intervention
Biological · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 24, 2026, 10:57 AM EDT
Recruiting No phase listed Observational

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

NCT03300830
View directory record Official record
Conditions
Human Immunodeficiency Virus, Castleman's Disease, Kaposi's Sarcoma, Viral-Associated Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 10:57 AM EDT
Not listed Phase 2 Interventional

Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma

NCT00041730
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Id-KLH
Biological
Lead sponsor
Favrille
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2009 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Not applicable Interventional

eFIT: An Internet-based Intervention to Increase Physical Activity in Persons With MS

NCT03829267
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
eFIT Intervention, eJournal Intervention, Treatment as usual
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Oral Immunotherapy for Wheat Allergy

NCT01980992
View directory record Official record
Conditions
Wheat Allergy
Interventions
Wheat OIT
Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
4 Years to 30 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

NCT00477971
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, dexamethasone, melphalan, autologous hematopoietic stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 1 Interventional

Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study

NCT02877771
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Insulin Pump
Interventions
t:slim insulin pump with predictive low glucose suspend
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
2
States / cities
Palo Alto, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 24, 2026, 10:57 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

COVID-19 Booster Vaccination in Persons With Multiple Sclerosis

NCT05081271
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Homologous booster, Heterologous booster
Biological
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Derby, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of an Oxalate Strip on Adjacent Teeth With Dentinal Hypersensitivity

NCT02293044
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Crest® Sensi-Stop™ Strips
Device
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 24, 2026, 10:57 AM EDT
Terminated Phase 2 Interventional Results available

Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03776864
View directory record Official record
Conditions
Hodgkin's Lymphoma
Interventions
Pembrolizumab, Umbralisib
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 24, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3BNC117 and 10-1074 in HIV Uninfected Adults

NCT02824536
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3BNC117, 10-1074, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 24, 2026, 10:57 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

NCT07146971
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
OTC Drug for Atopic Dermatitis in Cream form
Drug
Lead sponsor
Good Molecules, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 24, 2026, 10:57 AM EDT